• rdna origin
  • EXUBERA (insulin human rdna origin) (insulin human [rDNA origin]) Inhalation Powder is a white to off-white powder in a unit dose blister (fill mass, see Table 1 ). (rxlist.com)
  • Each unit dose blister of EXUBERA (insulin human rdna origin) contains a 1 mg or 3 mg dose of insulin (see Table 1 ) in a homogeneous powder formulation containing sodium citrate (dihydrate), mannitol, glycine , and sodium hydroxide. (rxlist.com)
  • After an EXUBERA (insulin human rdna origin) blister is inserted into the inhaler, the patient pumps the handle of the inhaler and then presses a button, causing the blister to be pierced. (rxlist.com)
  • Under standardized in vitro test conditions, EXUBERA (insulin human rdna origin) delivers a specific emitted dose of insulin from the mouthpiece of the inhaler (see Table 1 ). (rxlist.com)
  • In patients with type 1 diabetes , EXUBERA (insulin human [rdna origin]) should be used in regimens that include a longer-acting insulin. (rxlist.com)
  • In patients with type 2 diabetes , EXUBERA (insulin human [rdna origin]) can be used as monotherapy or in combination with oral agents or longer-acting insulins. (rxlist.com)
  • EXUBERA (insulin human [rdna origin]) doses should be administered immediately prior to meals (no more than 10 minutes prior to each meal). (rxlist.com)
  • EXUBERA (insulin human [rdna origin]) is intended for administration by inhalation and must only be administered using the EXUBERA (insulin human [rdna origin]) ® Inhaler. (rxlist.com)
  • Refer to the EXUBERA (insulin human [rdna origin]) Medication Guide for a description of the EXUBERA (insulin human [rdna origin]) ® Inhaler and for instructions on how to use the inhaler. (rxlist.com)
  • injections
  • Review of controlled trials shows that, in most patients, mean blood glucose concentrations and glycated hemoglobin percentages are either slightly lower or similar on CSII versus multiple insulin injections. (diabetesjournals.org)
  • This allowed larger amounts of active monomeric insulin to be available for postprandial (after meal) injections. (wikipedia.org)
  • pump
  • Is it then time to call a halt to the expansion of insulin pump therapy? (diabetesjournals.org)
  • But enthusiasm from some is mixed with uncertainty from others, who are concerned about the possible complications of pump therapy ( 22 ) or intensive insulin therapy in general ( 23 ). (diabetesjournals.org)
  • In the SAPT-NODAT study, we will employ sensor-augmented insulin-pump technology, which performs like a semi-closed loop to prevent hypoglycemic events. (clinicaltrials.gov)
  • Continuous subcutaneous sensor-augmented insulin-pump therapy (SAPT) with an insulin pump from Medtronic (Paradigm® Velo) for a period of approximately 3 months post-transplantation. (clinicaltrials.gov)
  • pancreatic
  • Returning to non-diabetic status depends on the amount of damage the pancreatic insulin-producing beta cells have sustained. (wikipedia.org)
  • absorption
  • these are soluble in the insulin vial rather than being suspensions, have more predictable absorption, achieve more constant blood levels, and have at least the potential for significantly improved control ( 8 , 9 ). (diabetesjournals.org)
  • A man injects insulin into his abdomen for quick absorption. (livestrong.com)
  • Moreover, the site of injection, volume of injection, and the condition of the tissues into which the insulin is injected can alter its rate of absorption and peak action times, and exercising the limb which has been injected immediately after injection can increase the speed of absorption. (thefreedictionary.com)
  • Through genetic engineering of the underlying DNA, the amino acid sequence of insulin can be changed to alter its ADME (absorption, distribution, metabolism, and excretion) characteristics. (wikipedia.org)
  • NPH (Neutral Protamine Hagedorn) insulin is an intermediate-acting insulin with delayed absorption after subcutaneous injection, used for basal insulin support in diabetes type 1 and type 2. (wikipedia.org)
  • fatty acids
  • Without insulin, glucose is unable to enter the cells where it will be used for this and other anabolic ("building up") purposes, such as the synthesis of glycogen, proteins, and fatty acids. (wikipedia.org)
  • Clinically
  • For the determination of the intra-individual rise in HbA1c, the previously observed rise of 0.5±0.7 % (mean ± standard deviation) from baseline to 3 months in the TIP-study basal insulin treatment group will be judged to be clinically not meaningful, hence if the intra-individual rise in the SAPT-treatment group remains below that value, the rise in HbA1c will be considered to be not meaningful, clinically. (clinicaltrials.gov)